Nasdaq

Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection ...

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart ...
Nasdaq

Cytokinetics opens enrollment for COMET-HF Phase 3 trial

Cytokinetics (CYTK) announced that COMET-HF, a confirmatory Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction, is open to ...
Hosted on MSN

Cytokinetics’ COMET-HF Study: A Potential Game-Changer for Heart Failure Treatment?

Cytokinetics ((CYTK)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
The Globe and Mail

Cytokinetics’ COMET-HF Study: A Potential Game-Changer for Heart Failure Treatment?

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: The COMET-HF study, ...